Potential drug candidates halt prostate and breast cancer growth

March 9, 2017

March 9, 2017 - Scientists on the Florida campus of The Scripps Research Institute (TSRI) have designed two new drug candidates to target prostate and triple negative breast cancers.

The new research, published recently as two separate studies in ACS Central Science and the Journal of the American Chemical Society, demonstrates that a new class of drugs called small molecule RNA inhibitors can successfully target and kill specific types of .

"This is like designing a scalpel to precisely seek out and destroy a cancer—but with a pill and without surgery," said TSRI Professor Matthew Disney, senior author of both studies.

A Tool to Fight Prostate Cancer

RNAs are molecules that translate our genetic code into proteins. RNA defects can lead to cancers, amyotrophic lateral sclerosis (ALS), myotonic dystrophy and many other diseases.

In their ACS Central Science study, Disney and his colleagues used DNA sequencing to evaluate thousands of small molecules as potential drug candidates. The researchers were on the lookout for molecules that could bind precisely with defective RNAs—like keys fitting in the right locks.

This strategy led them to a compound that targets the precursor molecule to an RNA called microRNA-18a. This RNA had caught the attention of scientists who found that mature microRNA-18a inhibits a protein that suppresses cancer. When microRNA-18a is overexpressed, cancers just keep growing.

Disney and his team tested their compound, called Targapremir-18a, and found that it could target microRNA-18a and trigger cell death.

"Since microRNA-18a is overexpressed in and helps to maintain them as cancerous, application of Targapremir-18a to cancer cells causes them to kill themselves," Disney said.

Disney said the precise binding of Targapremir-18a to microRNA-18a means a cancer drug that follows this strategy would be likely to kill without causing the broader side effects seen with many other cancer therapies.

And there may be even bigger implications. "We could apply the strategy used in this study to quickly identify and design small molecule drugs for other RNA-associated diseases," explained study first author Sai Velagapudi, a research associate in the Disney lab.

Testing the Strategy in Breast Cancer

The same screening strategy led the researchers to a drug candidate to target triple negative breast cancer, as reported in the Journal of the American Chemical Society.

Triple negative breast cancer is especially hard to treat because it lacks the receptors, such as the estrogen receptor, targeted with other cancer drugs. The Disney lab aimed to get around this problem by instead targeting an RNA called microRNA-210, which is overexpressed in solid breast cancer tumors.

The researchers tested their drug compound, Targapremir-210, in mouse models of triple negative . They found that the therapy significantly slowed down tumor growth. In fact, a single dose decreased tumor size by 60 percent over a three-week period. The researchers analyzed these smaller tumors and discovered that they also expressed less microRNA-210 compared with untreated tumors.

Targapremir-210 appears to work by reversing a circuit that tells cells to "survive at all costs" and become cancerous. With microRNA-210 in check, cells regain their normal function and cancer cannot grow.

"We believe Targapremir-210 can provide a potentially more precise, targeted therapy that would not harm healthy cells," said study first author TSRI Graduate Student Matthew G. Costales.

Next, the researchers plan to further develop their molecule-screening strategy into a platform to test molecules against any form of RNA defect-related disease.

Explore further: Scientists pioneer a breakthrough approach to breast cancer treatment

Related Stories

Scientists pioneer a breakthrough approach to breast cancer treatment

May 9, 2016
In a development that could lead to a new generation of drugs to precisely treat a range of diseases, scientists from the Florida campus of The Scripps Research Institute (TSRI) have for the first time designed a drug candidate ...

Researchers identify new potential treatment for cancer metastasis

January 9, 2017
Breast cancer metastasis, the process by which cancer spreads, may be prevented through the new use of a class of drugs already approved by the U.S. Food and Drug Administration.

Scientists uncover new way to defeat therapy-resistant prostate cancer

December 29, 2016
A new study led by scientists from the Florida campus of The Scripps Research Institute (TSRI) sheds light on a signaling circuit in cells that drives therapy resistance in prostate cancer. The researchers found that targeting ...

Double whammy for triple negative breast cancer

December 5, 2016
A promising new combination therapy for a particularly aggressive form of breast cancer has been identified by Weizmann Institute scientists, as was recently reported in Cancer Research. The potential dual-acting therapeutic ...

Natural compound found in herbs, vegetables could improve treatment of triple-negative breast cancer in women

January 23, 2017
More than 100 women die from breast cancer every day in the United States. Triple-negative breast cancers, which comprise 15 to 20 percent of all breast tumors, are a particularly deadly type of breast disease that often ...

Recommended for you

New findings explain how UV rays trigger skin cancer

October 18, 2017
Melanoma, a cancer of skin pigment cells called melanocytes, will strike an estimated 87,110 people in the U.S. in 2017, according to the Centers for Disease Control and Prevention. A fraction of those melanomas come from ...

Drug yields high response rates for lung cancer patients with harsh mutation

October 18, 2017
A targeted therapy resurrected by the Moon Shots Program at The University of Texas MD Anderson Cancer Center has produced unprecedented response rates among patients with metastatic non-small cell lung cancer that carries ...

Possible new immune therapy target in lung cancer

October 18, 2017
A study from Bern University Hospital in collaboration with the University of Bern shows that so-called perivascular-like cells from lung tumors behave abnormally. They not only inadequately support vascular structures, but ...

Many pelvic tumors in women may have common origin—fallopian tubes

October 17, 2017
Most—and possibly all—ovarian cancers start, not in ovaries, but instead in the fallopian tubes attached to them.

Researchers find novel mechanism of resistance to anti-cancer drugs

October 17, 2017
The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors ...

New bowel cancer drug target discovered

October 17, 2017
Researchers at the Francis Crick Institute have discovered a new drug target for bowel cancer that is specific to tumour cells and therefore less toxic than conventional therapies.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.